Equities

Cosma SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
COS:WSE

Cosma SA

Actions
  • Price (PLN)0.42
  • Today's Change0.00 / 0.00%
  • Shares traded955.00
  • 1 Year change-26.32%
  • Beta-0.3283
Data delayed at least 15 minutes, as of Feb 09 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cosma SA is a Poland-based company which is primarily engaged in the dietary supplements industry. The Company is also engaged in the hemp products industry. The Company sells products in the consumer health sector, as well as, in the raw materials and semi-finished products sector. The Company's products intended for people, are offered under the brands: Cosma and Full Spectrum. Pet products are offered under the brand Green Paw. The company offers range of products, such as hemp food (hemp protein, hemp seed, hemp oils, teas), dietary supplemements (oils with vitamins, oils with extracts plant), feed additives, cosmetics (lubricants, massage oils, intimate serum), cannabinoids, as well as, plant extracts (cannabidiol hemp distillate, cannabigerol hemp distillate, cannabidiol isolate, cannabigerol isolate).

  • Revenue in PLN (TTM)12.94m
  • Net income in PLN-23.34m
  • Incorporated2015
  • Employees30.00
  • Location
    Cosma SAPlac Europejski 1/P.40WARSZAWA 00-844PolandPOL
  • Phone+48 223507098
  • Fax+48 223507013
  • Websitehttps://cosma.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oxford Biodynamics PLC5.29m-53.93m59.13m44.00--5.00--11.17-0.0096-0.00960.00080.00060.10852.221.21---110.46-70.62-148.46-89.0347.67---1,018.54-1,715.570.8005-30.880.8208--72.1719.153.58---11.79--
Probiotix Health PLC10.74m-3.56m59.27m4.00--6.85--5.52-0.005-0.0050.01460.01131.0518.573.01555,250.00-34.67-21.03-46.17-27.3053.1754.10-33.14-26.583.99--0.00--12.5536.47-13.39---41.50--
Delta-Fly Pharma Inc0.00-37.28m60.05m13.00--7.07-----162.56-162.560.0030.840.00----0.00-352.25-88.06-490.58-97.02-------1,051.54---4,172.580.00-------20.41---61.24--
Biofrontera AG97.85m-8.99m60.35m76.00--0.9772--0.6168-0.3607-0.36073.822.441.091.2010.30290,725.00-9.98-11.66-13.30-15.1477.0082.87-9.19-20.212.090.60330.035---32.82-7.07-1,078.86---35.31--
Lexaria Bioscience Corp1.84m-38.11m60.72m7.00--3.13--32.94-0.5743-0.57430.02720.2210.0659--2.9774,571.43-136.35-102.60-145.39-105.78100.0087.95-2,069.41-1,579.38---285.300.00--52.0517.53-105.37--48.50--
Alpa Laboratories Limited43.36m7.24m61.05m453.008.440.85597.481.418.848.8452.0587.120.51055.072.852,459,994.008.528.5910.4910.6129.0833.7516.7013.403.83-15.290.00--3.415.5216.2560.1134.92--
Cosma SA12.94m-23.34m61.14m30.00--6.15--4.73-0.1635-0.16350.09340.06830.4352.146.00517,444.00-78.50---100.47--50.66---180.44--0.4173-92.620.2326--173.51--42.40------
TrivarX Ltd2.84m-2.36m63.56m4.00--1.08--22.41-0.0018-0.00180.00230.02040.0923-------7.68-33.47-8.32-37.46-----83.27-373.85---27.050.0132--26.383.8934.25--6.29--
Data as of Feb 09 2026. Currency figures normalised to Cosma SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.